曲安西龍市場 - 類型（乳膏、注射、吸入器）、應用（濕疹、皮膚炎、過敏、牛皮癬）、最終用戶（藥局、醫院） - 全球預測（2024 - 2032）

在快速的製藥進步和法規核准的推動下，曲安西龍市場規模預計在 2024 年至 2032 年期間複合年成長率將達到 3.4%。最近，研究人員正在開發新的配方，以增強曲安西龍的功效並減少副作用，使其更適合一系列醫療狀況。這些創新導致了給藥系統的改進，例如緩釋注射劑和局部應用。

因此，監管機構正在批准新的用途和配方，以擴大曲安西龍的治療應用範圍。例如，2024 年6 月，Harrow 宣布成功生產了三批商業規模PPQ 批次中的第一批Triesence，這是一種不含防腐劑的合成皮質類固醇，經FDA 批准用於玻璃體切除術期間的可視化以及治療對局部皮質類固醇無反應的眼部發炎。

曲安西龍產業按類型、應用程式、最終用戶和地區細分。

注射劑型細分市場的市場佔有率預計到 2032 年將大幅成長，這得益於注射劑在各種醫療條件下減少發炎和緩解疼痛的使用不斷增加。這些注射用於治療關節炎、過敏和皮膚病等疾病。此外，醫療保健提供者正在探索曲安西龍注射液對更廣泛疾病的益處。研究人員也正在開發新的配方，以提高這些注射劑的功效並最大限度地減少副作用。

在應用方面，過敏領域的曲安西龍市場預計將在 2024 年至 2032 年期間產生可觀的收入。透過減少發炎和緩解症狀來控制嚴重過敏的強烈需求推動了這一點。醫生正在為持續過敏反應的患者注射曲安奈德，以顯著緩解症狀。透過研究和完善針對過敏的產品用法，患者正在接受更精確和量身定做的治療，以幫助他們更有效地管理過敏並提高生活品質。

由於慢性病盛行率上升和人口迅速老化，歐洲曲安西龍產業規模到 2032 年可能會顯著成長。醫療保健提供者正在使用曲安西龍來控制關節炎、氣喘和嚴重過敏等疾病，這些疾病在老年人中更為常見。該地區的醫療專業人員正在專注於曲安西龍，以滿足老齡化人口和慢性病患者的需求。此外，研究人員正在開發新的配方和給藥方法，以提高有效性，確保整個歐洲的患者受益於先進的治療並改善生活品質。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 皮膚病的盛行率不斷增加
    • 提高及時治療皮膚問題的意識
    • 與曲安西龍結合使用的新型高效活性成分的可用性
    • 新的和先進的曲安西龍製劑的監管批准數量增加
  • 產業陷阱與挑戰
    • 與含氯氟碳化合物的曲安西龍軟膏相關的環境問題
    • 存在強烈效法製藥替代品
• 成長潛力分析
• 監管環境
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 競爭定位矩陣
• 戰略儀表板

第 5 章：市場估計與預測：按類型，2021 - 2032

• 主要趨勢
• 奶油
• 注射
• 吸入器
• 其他類型

第 6 章：市場估計與預測：按應用分類，2021 - 2032

• 主要趨勢
• 濕疹
• 皮膚炎
• 過敏
• 牛皮癬
• 其他應用

第 7 章：市場估計與預測：按最終用戶分類，2021 - 2032 年

• 主要趨勢
• 藥局
• 醫院
• 其他最終用戶

第 8 章：市場估計與預測：按地區，2021 - 2032

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 中東和非洲其他地區

第 9 章：公司簡介

• Alembic Pharmaceuticals Ltd.
• Alkem Laboratories Ltd.
• Bausch + Lomb Corporation
• Coral Drugs Pvt. Ltd.
• Crown Laboratories, Inc.
• G&W Laboratories, Inc.
• Lupin Ltd.
• Perrigo Company plc
• Sandoz AG
• Sanofi
• Taro Pharmaceutical Industries Ltd.
• Teligent Pharma, Inc.
• Teva Pharmaceutical Industries Ltd.
• WEEFSEL PHARMA
• Zydus Group

Triamcinolone Market size is expected to record a 3.4% CAGR between 2024 and 2032, driven by rapid pharmaceutical advancements and regulatory approvals. Lately, researchers are developing new formulations to enhance the efficacy of triamcinolone and reduce side effects, making it more suitable for a range of medical conditions. These innovations are leading to improved delivery systems, such as sustained-release injections and topical applications.

Consequently, regulatory bodies are approving new uses and formulations for expanding the scope of triamcinolone in therapeutic applications. For instance, in June 2024, Harrow announced the successful manufacture of the first of three commercial-scale PPQ batches of Triesence, a preservative-free synthetic corticosteroid FDA-approved for visualization during vitrectomy and treating ocular inflammatory conditions unresponsive to topical corticosteroids.

The triamcinolone industry is segmented into type, application, end-user, and region.

The market share from the injections type segment is expected to witness substantial growth through 2032, backed by their rising usage in various medical conditions for reducing inflammation and relieving pain. These injections are used to treat conditions, such as arthritis, allergies, and skin disorders. Moreover, healthcare providers are exploring the benefits of triamcinolone injections for a broader range of ailments. Researchers are also developing new formulations to enhance the efficacy and minimize the side effects of these injections.

In terms of application, the triamcinolone market from the allergies segment is slated to generate notable revenue during 2024-2032. This is favored by the strong need for managing severe allergies by reducing inflammation and alleviating symptoms. Doctors are administering triamcinolone injections to patients who are experiencing persistent allergic reactions for offering them significant relief. With researching and refining the product usage for allergies, patients are receiving more precise and tailored treatments to help them manage their allergies more effectively and improve their quality of life.

Europe triamcinolone industry size is likely to record a notable growth rate through 2032 driven by the increasing prevalence of chronic diseases and the rapidly aging population. Healthcare providers are administering triamcinolone to manage conditions, such as arthritis, asthma, and severe allergies, which are more common among older adults. Medical professionals in the region are focusing on triamcinolone to address the needs of the aging population and those with chronic illnesses. Furthermore, researchers are developing new formulations and delivery methods to enhance effectiveness for ensuring that patients are benefiting from advanced treatments and experiencing improved quality of life across Europe.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of skin conditions
    • 3.2.1.2 Increasing awareness towards timely treatment of skin issues
    • 3.2.1.3 Availability of new and efficient active ingredients to combine with triamcinolone
    • 3.2.1.4 Growth in regulatory approval of new and advanced triamcinolone formulations
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Environmental concerns related to chlorofluorocarbon-based triamcinolone ointments
    • 3.2.2.2 Presence of strong generic substitutes
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Porter's analysis
• 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Cream
• 5.3 Injections
• 5.4 Inhalers
• 5.5 Other types

Chapter 6 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Eczema
• 6.3 Dermatitis
• 6.4 Allergies
• 6.5 Psoriasis
• 6.6 Other applications

Chapter 7 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Drug stores
• 7.3 Hospitals
• 7.4 Other end-users

Chapter 8 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 France
  • 8.3.4 Spain
  • 8.3.5 Italy
  • 8.3.6 Netherlands
  • 8.3.7 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 South Korea
  • 8.4.6 Rest of Asia Pacific
• 8.5 Latin America
  • 8.5.1 Brazil
  • 8.5.2 Mexico
  • 8.5.3 Rest of Latin America
• 8.6 Middle East and Africa
  • 8.6.1 South Africa
  • 8.6.2 Saudi Arabia
  • 8.6.3 UAE
  • 8.6.4 Rest of Middle East and Africa

Chapter 9 Company Profiles

• 9.1 Alembic Pharmaceuticals Ltd.
• 9.2 Alkem Laboratories Ltd.
• 9.3 Bausch + Lomb Corporation
• 9.4 Coral Drugs Pvt. Ltd.
• 9.5 Crown Laboratories, Inc.
• 9.6 G&W Laboratories, Inc.
• 9.7 Lupin Ltd.
• 9.8 Perrigo Company plc
• 9.9 Sandoz AG
• 9.10 Sanofi
• 9.11 Taro Pharmaceutical Industries Ltd.
• 9.12 Teligent Pharma, Inc.
• 9.13 Teva Pharmaceutical Industries Ltd.
• 9.14 WEEFSEL PHARMA
• 9.15 Zydus Group